You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動 | 康方生物飆漲近25%,與Summit訂立依沃西高達50億美元許可協議
uSMART盈立智投 12-07 09:58

智通財經APP獲悉,$康方生物-B(09926.HK)$持續走高,截至發稿,漲24.72%,報38.85港元,成交額2.02億港元。

消息面上,12月6日,康方生物宣佈,將授予Summit  Therapeutics於美國、加拿大、歐洲和日本的開發和商業化依沃西的獨家許可權。康方生物將獲得5億美元的首付款。包括開發、註冊及商業化裏程碑款項付款,該交易總金額有望高達50億美元。同時,也將獲得依沃西產品銷售淨額的低雙位數百分比的提成,作爲特許權使用費。

據悉,依沃西是公司自主研發,全球行業內首個進入III期臨牀研究的PD-1/VEGF雙特異性抗體。依沃西是基於公司獨特的Tetrabody技術設計,可阻斷PD-1與PD-L1和PD-L2的結合,並同時阻斷VEGF與VEGF受體的結合。PD-1抗體與VEGF阻斷劑的聯合療法已在多種瘤種(包括腎細胞癌、非小細胞肺癌和肝細胞癌)中顯示出強大的療效。

此外,康方生物公佈,於2022年12月5日,董事會決議公司擬發行將於上海證券交易所科創板上市並以人民幣買賣的普通股。建議發行人民幣股份取決於及受限於(  其中包括 )市場狀況、董事會的進一步批準、股東於公司股東大會上的批準及必要監管機構的批準。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account